Adapt Pharma Inc. failed to convince the Federal Circuit to revive its four patents on the Narcan opioid overdose treatment felled by
The U.S. District Court for the District of New Jersey had invalidated the patents as obvious, paving the way for Teva and others to make generic versions of the nasal spray 15 years earlier than if the patents were allowed to expire.
A divided U.S. Court of Appeals for the Federal Circuit panel upheld the trial court’s ruling in a precedential opinion Thursday, agreeing that using a naloxone nasal spray to treat opioid overdose ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.